Ceftriaxone-and-cefixime-resistant Neisseria gonorrhoeae in a 26-year-old-male with gonococcal urethritis: a case report
Main Article Content
Keywords
cefixime, ceftriaxone, gonococcal urethritis, Neisseria gonorrhoeae
Abstract
Introduction: Gonorrhoea is the most prevalent sexually transmitted infection (STI) in Indonesia. The increasing resistance of Neisseria gonorrhoeae to antibiotics has prompted the World Health Organization (WHO) to classify gonorrhoea as an urgent public health threat. Reports of resistance to third generation extended-spectrum cephalosporins (ESCs), such as cefixime and ceftriaxone, against N. gonorrhoeae are rare in Indonesia. This study aims to present a case of cefixime and ceftriaxone resistance in a 26-year-old man with gonococcal urethritis.
Case Description: A 26-year-old man presented to an STI clinic with a two-week history of increased urethral discharge. He reported a history of sexual activity with multiple partners. Physical examination revealed mucopurulent exudate and thick greenish-white pus from the external genitalia. Microscopic examination of a urethral smear identified numerous polymorphonuclear cells (>10 PMN/high-power field) and Gram-negative intracellular diplococci. Bacterial culture confirmed the presence of Gram-negative diplococci consistent with N. gonorrhoeae. Polymerase chain reaction (PCR) testing further confirmed N. gonorrhoeae. Susceptibility testing revealed resistance to both cefixime and ceftriaxone. The patient was treated with dual therapy, consisting of a single oral dose of azithromycin (1 g) and cefixime (400 mg). Complete symptom resolution was achieved within one week.
Conclusion: Third-generation ESCs, including injectable ceftriaxone and orally administered cefixime, are the most commonly used antibiotics for gonorrhoea treatment. Resistance to these drugs represents a significant global health threat. Discrepancies between antibiotic susceptibility test results and clinical outcomes highlight the need for further investigation into underlying factors contributing to treatment efficacy.
References
2. Chen X, Chen S, Li C, Shi L, Zhu Y, Yao Y. Analysis and prediction of the incidence and prevalence trends of gonorrhea in China. Hum Vaccines Immunother [Internet]. 2023;19(2). Available from: https://doi.org/10.1080/21645515.2023.2256907
3. Zeng F, Shen Y, Du N, Wu L, Fei L, Wang Y, et al. Spatiotemporal Epidemiology of the Gonorrhea Epidemic in Relation to Neighborhood-level Structural Factors in an Eastern Province of China, 2016-2020. Altern Ther Health Med. 2023;29(6):350–7.
4. Ministry of Health Republic of Indonesia – Directorate General of Disease Control and Environmental Health. Technical Guidelines for Gonococcal Antimicrobial Surveillance. Afriana N, editor. Jakarta; 2023. 2 p.
5. Global HIV H and STIP. Enhanced Gonococcal Antimicrobial Surveillance Programme (EGASP): general protocol [Internet]. World Health Organization (WHO). 2021. Available from: https://iris.who.int/bitstream/handle/10665/341333/9789240021341-eng.pdf?sequence=1
6. Rizal Y. The Relationship between the Behavior of How to Get Treatment in Men Suffering from Non-Complicated Acute Gonorrheal Urethritis and Drug Resistance [Internet]. Faculty of Medicine Andalas University; 2011. Available from: https://issuu.com/indosiana/docs/hubungan_prilaku_cara_mendapatkan_p
7. Setyowatie L, SHW T, Yulian I. Susceptibility Pattern of Neisseria gonorrhoeae towards Cefixime and Ceftriaxone using Kirby-Bauer Method in Dr. Saiful Anwar General Hospital Malang. Berk Ilmu Kesehat Kulit dan Kelamin. 2020;32(2):103.
8. Unemo M, Shafer WM. Antimicrobial resistance in Neisseria gonorrhoeae in the 21st Century: Past, evolution, and future. Clin Microbiol Rev. 2014;27(3):587–613.
9. Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial Susceptibility Testing:CLSI supplement M100. Vol. 8, Journal of Services Marketing. 2023. 1–358 p.
10. Quillin SJ, Seifert HS. Neisseria gonorrhoeae host adaptation and pathogenesis. Nat Rev Microbiol [Internet]. 2018;16(4):226–40. Available from: http://dx.doi.org/10.1038/nrmicro.2017.169
11. Viera Valencia LF, Garcia Giraldo D. Jawetz, Melnick, & Adelberg’s Medical Microbiology. Vol. 2, Angewandte Chemie International Edition, 6(11), 951–952. 2019.
12. Meyer T, Buder S. The laboratory diagnosis of neisseria gonorrhoeae: Current testing and future demands. Pathogens. 2020;9(2):1–19.
13. Unemo M, Rio C Del, Shafer WM. Antimicrobial resistance expressed by neisseria gonorrhoeae: A major global public health problem in the 21st century. Emerg Infect 10. 2016;213–37.
14. Gould IM. Towards a common susceptibility testing method? J Antimicrob Chemother. 2000;45(6):757–62.
15. Doern G V., Brecher SM. The clinical predictive value (or lack thereof) of the results of in vitro antimicrobial susceptibility tests. J Clin Microbiol. 2011;49(9 SUPPL.):11–4.